Introduction {#sec1}
============

From this century, miRNAs were considered as star molecules, instead of 'trash', as they worked as a regulatory element for the post-translation of mRNA \[[@B1]\]. miRNAs were also generated from the genome DNA and could transcript and translate into mature miRNA, which was executed in two steps: from pri-miRNA to pre-miRNA, and from pre-miRNA to mature miRNA \[[@B2]\]. As miRNA is small (19--24 nt long) \[[@B3]\], it has the characteristic of stability and thus, has the potential to be the biomarker for the detection in tissues, or even in serum or urine \[[@B4]\]. Other characteristics of miRNA are: first, it could complementarily combine with multiple target sequences and one miRNA could regulate multiple different target genes \[[@B1]\]; second, it has little chance to vary or to mutate \[[@B5]\]. But, if there is a variation in the formation process of miRNA, it could affect the quality and quantity of mature miRNA and even affect hundreds of targeted genes regulated by the changed miRNA \[[@B6]\].

Single nucleotide polymorphisms (SNPs) are the common variation in the genetic polymorphisms and are known as the potential biomarkers for the forecast in cancer risk and predicting the cancer prognosis \[[@B7]\]. Pri-miRNA and pre-miRNA have SNPs which were studied to be associated with cancer risk and prognosis \[[@B8],[@B9]\]. As pri-miRNA is always 500--3000 bp long and pre-miRNA is 60--70 bp long, the existence of pre-miRNA SNPs is limited, and pri-miRNA SNPs are more relative and reported to affect the function of miRNAs \[[@B5]\].

*Let-7* family is one of the earliest found miRNAs and composed of ten kinds of miRNAs (*let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-98*, and *miR-202*) \[[@B10]\]. *Let-7* family is the most important miRNA acting on carcinogenesis, as Krol et al. found, the pri-miRNA of *let-7* family could combine with LIN28 and suppress the splicing procedure of Drosha and Dicer, two important restriction enzymes involved in the maturation process for all miRNAs \[[@B11]\]. In addition, by knocking down the Drosha enzyme to suppress all the miRNA maturation processes comprehensively, Kumar et al. found that the main reason for the activation and promotion of cell's malignant transformation was the downregulation of *let-7* family expression \[[@B12]\]. Thus, *let-7* family is essential to suppress the cancer cells' proliferation, and plays important roles in the carcinogenesis process \[[@B13]\]. The *let-7* genetic polymorphisms could have participated in the carcinogenesis process.

The *let-7* genetic polymorphisms were reported to be associated with cancer risk and prognosis, but the results were inconsistent. For example, Jing Liu et al. found the *let-7i* promoter rs10877887 SNP variant C allele could increase cancer risk (odds ratio (OR) = 1.35) \[[@B14]\] while others found the variant C allele could decrease cancer risk \[[@B15],[@B16]\]. Thus, a comprehensive analysis which integrated all individual studies concerning this rs10877887 SNP and all cancer risk/prognosis is still required, as well as all the *let-7* family polymorphisms. And until now, a system review or a meta-analysis for the *let-7* family polymorphisms was none. These data could expand our understanding of the role of *let-7* polymorphisms in human carcinogenesis, which may provide some evidence for future research. Therefore, we systematically reviewed published data and meta-analyzed for *let-7* family polymorphisms to give a comprehensive assessment for the associations of *let-7* SNPs and cancer risks/prognosis.

Methods {#sec2}
=======

Publication search {#sec2-1}
------------------

A literature searching was executed systematically and comprehensively by two independent investigators (B.G.W. and Q.X.), up to April 18, 2018. The databases contain PubMed, Web of Science, Embase and Chinese National Knowledge Infrastructure (CNKI) using the following key words: '*let-7*/pri-*let-7*', 'SNP/polymorphisms/variation/variant', and 'cancer/carcinoma/tumor/neoplasm'. The major inclusion criteria were the literatures concerning the correlation between *let-7* polymorphisms and cancer risks/prognosis. When the literature met the followings: (1) reviews or meta-analysis, (2) duplicate records, (3) study for benign disease compared with controls, (4) unrelated to cancer or *let-7* polymorphisms; it was judged as the exclusion criteria.

Data extraction {#sec2-2}
---------------

Two authors (B.G.W. and Q.X.) extracted all the data independently, and finally reached a consensus on all the items. In the risk study, the following items were collected: first author, publication year, ethnicity, cancer type, genotyping method, source of control groups (population-based or hospital-based), total number of controls, and cases, and genotype distributions in controls and cases. In the prognosis study, the following information was extracted from the article: first author, publication year, study population, SNP names, compared genetic model, cancer type, sample size, and hazard ratio (HR) estimation. When the data in eligible articles were unavailable, we tried our best to contact the corresponding authors for original data.

Methodology quality assessment {#sec2-3}
------------------------------

Quality of the selected studies was assessed according to a study regarding the method for assigning quality scores, which was mentioned in prior meta-analysis \[[@B17]\]. Six items were evaluated in the quality assessment scale: (1) the representativeness of the cases; (2) the source of controls; (3) the ascertainment of relevant cancers; (4) the sample size; (5) the quality control of the genotyping methods; (6) and Hardy--Weinberg equilibrium (HWE) in controls. The details see Supplementary Table S1. The quality scores of eligible studies ranged from 0 to 10. Studies with a score less than 5 and HWE disequilibrium were removed from the subsequent analyses.

Trial sequential analysis and false-positive report probability analysis {#sec2-4}
------------------------------------------------------------------------

Trial sequential analysis (TSA) was performed as described by user manual for TSA \[[@B18]\]. In brief, TSA software was downloaded from the website ([www.ctu.dk/tsa](http://www.ctu.dk/tsa)). After adopting a level of significance of 5% for type I error and of 30% for type II error, the required information size was calculated, and TSA monitoring boundaries were built \[[@B19],[@B20]\].

The false-positive report probability (FPRP) values at different prior probability levels for all significant findings were calculated as published reference studies \[[@B21]\]. Briefly, 0.2 was set as FPRP threshold and assigned a prior probability of 0.01 for an association with genotypes under investigation. A FPRP value \<0.2 denoted a noteworthy association.

Statistics {#sec2-5}
----------

The HWE was calculated by the Chi-square test in control groups for genotype frequencies of *let-7* polymorphisms. The strength of the association between *let-7* polymorphisms and cancer susceptibility was measured by ORs and the relationship between *let-7* polymorphisms and cancer prognosis was evaluated by HRs. We calculated the between-study heterogeneity by the Cochran's Q test and quantified by *I^2^* (a significance level of *P*\<0.10). When heterogeneity did not exist, a fixed-effect model was employed \[[@B24]\]; otherwise, a random-effect model was used \[[@B25]\]. A total of five comparison models were conducted, namely heterozygote comparison (CT compared with TT), homozygote comparison (CC compared with TT), dominant model (CT + CC compared with TT), recessive model (CC compared with CT + TT), and allelic model (C compared with T).

Further, we executed stratification analyses on cancer type, source of controls (population-based and hospital-based study design), and sample size (total samples \> 1000 or \< 1000). The Begg's rank correlation and the Egger's linear regression were evaluated for the publication bias \[[@B26],[@B27]\] (*P*\<0.10 as reached statistically significant). All analyses were performed by STATA software, version 11.0 (STATA Corp., College Station, TX, U.S.A.).

Results {#sec3}
=======

Characteristics of the studies {#sec3-1}
------------------------------

After duplicate literatures removed, 172 records in total were using different combinations of the major keywords. First, according to the title or abstracts screening, we excluded 81 articles (amongst them, 67 were function studies and 14 were reviews or meta-analyses). Second, after full-text reading, 81 studies were excluded (73 were not about *let-7* polymorphisms but for the *let-7* target gene polymorphisms, 7 were not associated with cancer and 1 was not case--control study). Finally, ten studies that met our inclusion criteria were included in our system review and meta-analysis, which consisted of 3837 cancer patients and 4745 controls in the risk study and 1665 cancer patients in the prognosis study ([Figure 1](#F1){ref-type="fig"}). The characteristics of each study in the risk study were shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, while in the prognosis study, were presented in [Table 3](#T3){ref-type="table"}. This meta-analysis complied with PROSMA 2009 Checklist, and for details, see Supplementary Table S2. Amongst these ten studies, two SNPs in *let-7* family were found in risk study (*let-7i* rs10877887 and *let-7a-1/let-7f-1/let-7d* rs13293512) and three SNPs (*let-7i* rs10877887, *let-7a-1* rs10739971, and *let-7a-2* rs629367) were found in prognosis study.

![Studies identified in this meta-analysis based on the criteria for inclusion and exclusion](bsr-38-bsr20180273-g1){#F1}

###### Characteristics of reviewed literatures for the *let-7* family polymorphisms

  Number   First author   Year   Ethnicity   Cancer type                        Genotyping method                 Source of control groups   Sample size   miRNAs   Quality score                                 Citation   
  -------- -------------- ------ ----------- ---------------------------------- --------------------------------- -------------------------- ------------- -------- --------------------------------------------- ---------- ------------
  1        Jing Liu       2018   Asian       Cervical squamous cell carcinoma   PCR-RFLP                          HB                         331           358      rs10877887; rs13293512                        7.5        \[[@B14]\]
  2        ZY Sui         2016   Asian       Hepatocellular cancer              Sequencing                        HB                         89            95       rs10877887                                    6.0        \[[@B34]\]
  3        LQ Shen        2015   Asian       Lung adenocarcinoma                Sequencing                        HB                         69            75       rs10877887                                    6.0        \[[@B35]\]
  4        Yichao Wang    2015   Asian       Papillary thyroid carcinoma        PCR-RFLP                          HB                         618           562      rs10877887; rs13293512                        8.5        \[[@B15]\]
  5        Yu Zhang       2014   Asian       Oral cavity cancer                 Taqman                            PB                         384           731      rs10877887                                    8.5        \[[@B16]\]
  6        Longbiao Zhu   2014   Asian       Head and neck cancer               Sequencing                        PB                         497           884      rs10877887; rs13293512                        8.5        \[[@B31]\]
  7        Qian Xu        2014   Asian       Gastric cancer                     PCR-RFLP; Sequencing; MassAssay   PB                         579           721      rs629367; rs1143770; rs10739971; rs17276588   8.5        \[[@B29]\]
  8        Fang Huang     2011   Asian       Hepatocellular cancer              Taqman                            HB                         1270          1319     rs10877887; rs13293512                        7.0        \[[@B28]\]

HB, hospital based; PB, population based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

###### The detailed data for the *let-7* family meta-analysis

  First author   miRNAs       Year   Cancer type                        Source of control groups   Sample size   Case   Control   *P* of HWE                           
  -------------- ------------ ------ ---------------------------------- -------------------------- ------------- ------ --------- ------------ ----- ----- ----- ----- -------
  Jing Liu       rs10877887   2018   Cervical squamous cell carcinoma   HB                         331           358    140       131          60    169   155   34    0.860
  ZY Sui         rs10877887   2016   Hepatocellular cancer              HB                         89            95     25        64           64    55    40    40    0.482
  LQ Shen        rs10877887   2015   Lung adenocarcinoma                HB                         69            75     20        44           5     34    37    4     0.552
  Yichao Wang    rs10877887   2015   Papillary thyroid carcinoma        HB                         618           562    325       224          69    262   248   52    0.541
  Yu Zhang       rs10877887   2014   Oral cavity cancer                 PB                         384           731    172       165          41    291   343   82    0.205
  Fang Huang     rs10877887   2011   Hepatocellular cancer              HB                         1261          1319   542       564          155   581   585   153   0.756
  Longbiao Zhu   rs10877887   2014   Head and neck cancer               PB                         497           884    227       213          57    361   422   101   0.179
  Jing Liu       rs13293512   2018   Cervical squamous cell carcinoma   HB                         331           358    97        163          71    105   186   67    0.340
  Yichao Wang    rs13293512   2015   Papillary thyroid carcinoma        HB                         618           562    165       333          120   158   300   104   0.066
  Fang Huang     rs13293512   2011   Hepatocellular cancer              HB                         1270          1291   406       611          253   427   638   226   0.642
  Longbiao Zhu   rs13293512   2014   Head and neck cancer               PB                         492           893    157       257          78    270   439   184   0.821

###### The characteristics of miRNA SNPs in the prognosis study

  Author name      Publication year   Study population   miRNA-SNPs   Model                      Cancer type                  Sample size   Outcome   HR     95% upper   95% lower   Citation
  ---------------- ------------------ ------------------ ------------ -------------------------- ---------------------------- ------------- --------- ------ ----------- ----------- ------------
  Kyung Min Shin   2016               Korea              rs1143770    CT + TT compared with CC   Non-small-cell lung cancer   761           OS        0.52   0.79        0.34        \[[@B36]\]
  Kyung Min Shin   2016               Korea              rs629367     CC compared with AA        Non-small-cell lung cancer   761           OS        0.92   1.89        0.45        \[[@B36]\]
  Kyung Min Shin   2016               Korea              rs10739971   GA + AA compared with GG   Non-small-cell lung cancer   761           OS        1.03   1.42        0.75        \[[@B36]\]
  Kyung Min Shin   2016               Korea              rs17276588   GA + AA compared with GG   Non-small-cell lung cancer   761           OS        1.06   1.31        0.86        \[[@B36]\]
  ZY Sui           2016               China              rs10877887   TT compared with CT + CC   Hepatocellular cancer        89            OS        0.68   0.94        0.52        \[[@B34]\]
  Kaipeng Xie      2013               China              rs10877887   CT + CC compared with TT   Hepatocellular cancer        331           OS        1.23   1.58        0.96        \[[@B36]\]
  Kaipeng Xie      2013               China              rs13293512   CT + CC compared with TT   Hepatocellular cancer        331           OS        0.93   1.22        0.71        \[[@B36]\]
  Ying Li          2015               China              rs10739971   GA + AA compared with GG   Gastric cancer               334           OS        1.32   4.8         0.36        \[[@B37]\]
  Qian Xu          2014               China              rs629367     CC compared with AA        Gastric cancer               150           OS        4.8    12.6        1.6         \[[@B29]\]

OS, overall survival.

In the risk study, all studies were matched for age; however, only seven studies were matched for sex; the other one did not need sex matching. The controls of five studies were HB, while others were PB; genotyping methods included PCR-RFLP, qPCR and sequencing. All genotypes were checked for quality control and were consistent with HWE. And according to the methodology quality assessment, the studies with a score less than 5 would be removed from the subsequent analyses. All the studies were above a score of 6.0 and recruited into the following analyses.

Quantitative synthesis for the association of SNPs and cancer susceptibility {#sec3-2}
----------------------------------------------------------------------------

For the *let-7i* rs10877887 SNP, the dominate model could collect seven studies while other genetic model could collect six studies. In all the five genetic models, none was shown a significant association between *let-7i* rs10877887 SNP and overall cancer risk except the recessive model. In the recessive model, when compared with *let-7i* rs10877887 TT + TC genotype, the variant CC genotype was nearly associated with the overall cancer risk, and the *P*-value reached 0.066 (OR = 1.15; 95% confidence interval (CI) = 0.99--1.33). For the other SNP rs13293512, no association was found between the SNP and overall cancer risk ([Table 4](#T4){ref-type="table"}).

###### Pooled ORs and 95% CIs of stratified meta-analysis for the risk study

  Stratification            Genotype                   N   OR (95% CI)             Z          *P*-value   Model   I^2^(%)
  ------------------------- -------------------------- --- ----------------------- ---------- ----------- ------- -----------------------------------------
  rs10877887                                                                                                      
  All cancers                                                                                                     
                            TC compared with TT        6   0.91 (0.76--1.09)       1.04       0.300       R       60.7
                            CC compared with TT        6   1.13 (0.87--1.46)       0.93       0.351       R       54.3
                            TC + CC compared with TT   7   1.10 (0.86--1.40)       0.77       0.443       R       80.9
                            CC compared with TT + TC   6   1.15 (0.99--1.33)       1.84       0.066       F       45.1
                            C compared with T          6   1.02 (0.89--1.16)       0.28       0.783       R       65.4
  Cancer type                                                                                                     
    Hepatocellular cancer                                                                                         
                            CC compared with TT + TC   2   1.85 (0.56--6.06)       1.01       0.312       R       92.9
    Head and neck cancer                                                                                          
                            TC compared with TT        2   **0.81 (0.68--0.96)**   **2.39**   **0.017**   F       0.0
                            CC compared with TT        2   0.88 (0.66--1.15)       0.95       0.341       F       0.0
                            TC + CC compared with TT   2   **0.82 (0.70--0.97)**   **2.33**   **0.020**   F       0.0
                            CC compared with TT + TC   2   0.98 (0.75--1.27)       0.18       0.857       F       0.0
                            C compared with T          2   0.89 (0.76--1.06)       1.80       0.072       F       0.0
  Source of controls                                                                                              
    HB                                                                                                            
                            TC compared with TT        4   1.00 (0.76--1.31)       0.02       0.982       R       70.5
                            CC compared with TT        4   1.33 (0.94--1.90)       1.59       0.111       R       57.6
                            TC + CC compared with TT   5   0.82 (0.70--0.97)       1.55       0.122       R       84.2
                            CC compared with TT + TC   4   1.35 (0.97--1.88)       1.76       0.079       R       56.4
                            C compared with T          4   1.11 (0.92--1.33)       1.11       0.269       R       68.5
    PB                                                                                                            
                            TC compared with TT        2   **0.81 (0.68--0.96)**   **2.39**   **0.017**   F       0.0
                            CC compared with TT        2   0.88 (0.66--1.15)       0.95       0.341       F       0.0
                            TC + CC compared with TT   2   **0.82 (0.70--0.97)**   **2.33**   **0.020**   F       0.0
                            CC compared with TT + TC   2   0.98 (0.75--1.27)       0.18       0.857       F       0.0
                            C compared with T          2   0.89 (0.79--1.01)       1.30       0.072       F       0.0
  Sample size                                                                                                     
    Large                                                                                                         
                            TC compared with TT        4   0.85 (0.72--1.01)       1.86       0.064       R       56.7
                            CC compared with TT        4   1.00 (0.84--1.18)       0.02       0.985       F       0.0
                            TC + CC compared with TT   4   **0.90 (0.82--1.00)**   **1.98**   **0.048**   F       50.0[^a^](#T4TFN1){ref-type="table-fn"}
                            CC compared with TT + TC   4   1.06 (0.90--1.24)       0.71       0.478       F       0.0
                            C compared with T          4   0.96 (0.89--1.03)       1.14       0.256       F       15.9
    Small                                                                                                         
                            TC compared with TT        2   1.33 (0.69--2.56)       0.86       0.389       R       66.6
                            CC compared with TT        2   **2.13 (1.36--3.35)**   **3.28**   **0.001**   F       0.0
                            TC + CC compared with TT   3   **1.98(1.01--3.88)**    **1.98**   **0.048**   R       79.7
                            CC compared with TT + TC   2   **2.03 (1.32--3.10)**   **3.24**   **0.001**   F       0.0
                            C compared with T          2   **1.38 (1.12--1.68)**   **3.08**   **0.002**   F       0.0
  rs13293512                                                                                                      
  All cancers                                                                                                     
                            TC compared with TT        4   1.01 (0.90--1.14)       0.18       0.861       F       0.0
                            CC compared with TT        4   1.04 (0.90--1.22)       0.55       0.579       F       49.5
                            TC + CC compared with TT   4   1.02 (0.91--1.14)       0.34       0.731       F       0.0
                            CC compared with TT + TC   4   1.02 (0.81--1.28)       0.17       0.869       R       61.2
                            C compared with T          4   1.02 (0.95--1.10)       0.52       0.603       F       34.6

*P*~heterogeneity~ is 0.112 which is higher than 0.10, thus fixed model has been used.

Furthermore, we executed stratification analysis based on different cancer types, source of controls, and sample size ([Table 4](#T4){ref-type="table"}). When the oral cavity cancer was divided into the head and neck cancer, the rs10877887 variant genotype was significantly associated with a decreased cancer risk in head and neck cancer (TC compared with TT: *P*=0.017; OR = 0.81; 95% CI = 0.68--0.96; TC + CC compared with TT: *P*=0.020; OR = 0.82; 95% CI = 0.70--0.97; [Figure 2](#F2){ref-type="fig"}A). When stratified by sample size, in the small sample size subgroup, the variant genotype showed an increased significant association between rs10877887 and overall cancer risks in four genetic models (CC compared with TT: *P*=0.001; OR = 2.13; 95% CI = 1.36--3.35; TC + CC compared with TT: *P*=0.048; OR = 1.98; 95% CI = 1.01--3.88; CC compared with TT + TC: *P*=0.001; OR = 2.03; 95% CI = 1.32--3.10; C compared with T: *P*=0.002; OR = 1.38; 95% CI = 1.12--1.68; [Table 4](#T4){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}B). While in the large sample size subgroup, rs10877887 SNP showed a decreased risk in the dominate model (*P*=0.048; OR = 0.90; 95% CI = 0.82--1.00; [Table 4](#T4){ref-type="table"}).

![Forest plot of ORs for the association of *let-7i* rs10877887 polymorphism with cancer risks and is illustrated in subgroup analysis\
(**A**) Stratified by cancer type in dominate model. (**B**) Stratified by sample size in recessive model.](bsr-38-bsr20180273-g2){#F2}

Quantitative synthesis for the association of SNPs and cancer prognosis {#sec3-3}
-----------------------------------------------------------------------

Then, we analyzed the association of *let-7* family polymorphisms and cancer overall survival. The *let-7i* rs10877887 SNP was shown to be associated with a higher risk for cancer prognosis in the dominate model (CT + CC compared with TT: *P*=0.004; HR = 1.32; 95% CI = 1.09--1.60; [Table 5](#T5){ref-type="table"}). The other two SNPs (*let-7a-1* rs10739971 and *let-7a-2* rs629367) were not found to be associated with cancer survival.

###### The meta-analysis results for the association of miRNA SNPs and cancer prognosis

  miRNA-SNPs   Model                      Number of studies   Number of patients   HR (95% CI)             *P*         Heterogeneity (*P*)
  ------------ -------------------------- ------------------- -------------------- ----------------------- ----------- ---------------------
  rs10877887   CT + CC compared with TT   2                   420                  **1.32 (1.09--1.60)**   **0.004**   0.367
  rs629367     CC compared with AA        2                   911                  2.01 (0.40--10.14)      0.130       0.010
  rs10739971   GA + AA compared with GG   2                   1095                 1.05 (0.77--1.42)       0.782       0.800

Heterogeneity {#sec3-4}
-------------

Several comparisons appeared for slight heterogeneities between studies which were shown in [Table 4](#T4){ref-type="table"}. We further performed sensitivity analyses to explore individual study's influence on the pooled results by removing one study at a time from pooled analysis (Supplementary Table S3). Any significant heterogeneity was not found in any genetic models which suggested a relative reliable result.

Publication bias {#sec3-5}
----------------

Begg's rank correlation and Egger's linear regression were conducted to evaluate publication bias. A slight publication bias for rs10877887 in dominate model was indicated according to the results of Begg's test and Egger's test (Supplementary Table S4).

TSA and FPRP analyses {#sec3-6}
---------------------

Amongst the positive results, we found the dominate model for *let-7i* rs10877887 SNP in the larger sample size subgroup was adopted for the TSA to strengthen the robustness of our findings. According to TSA result, the required information size was 14,497 subjects to demonstrate the issue ([Figure 3](#F3){ref-type="fig"}). Until now, the cumulative z-curve has not crossed the trial monitoring boundary before reaching the required information size, indicating that the cumulative evidence is insufficient and further trials are necessary.

![The required information size to demonstrate the relevance of *let-7i* rs10877887 polymorphism with risk of cancer in the larger sample size subgroup (dominate model)](bsr-38-bsr20180273-g3){#F3}

Then, we calculated the FPRP values for all observed significant findings. With the assumption of a prior probability of 0.01, the FPRP values for the small sample size subgroup in the co-dominate (CC compared with TT), recessive and allelic models were all \<0.20, suggesting that these significant associations were noteworthy ([Table 6](#T6){ref-type="table"}).

###### FPRP values for the associations between *let-7* rs10877887 polymorphism and overall cancer risk

                                                                 Prior probability                           
  -------------------------- ------------------- ------- ------- ------------------- ------- ------- ------- -------
  TC compared with TT                                                                                        
    Head and neck cancer     0.81 (0.68--0.96)   0.017   0.666   0.071               0.187   0.716   0.962   0.996
    PB                       0.81 (0.68--0.96)   0.017   0.666   0.071               0.187   0.716   0.962   0.996
                                                                                                             
  CC compared with TT                                                                                        
    Small sample size        2.13 (1.36--3.35)   0.001   0.922   0.003               0.010   0.097   0.520   0.916
                                                                                                             
  TC + CC compared with TT                                                                                   
    Head and neck cancer     0.82 (0.70--0.97)   0.020   0.635   0.086               0.221   0.757   0.969   0.997
    PB                       0.82 (0.70--0.97)   0.020   0.635   0.086               0.221   0.757   0.969   0.997
    Large sample size        0.90 (0.82--1.00)   0.048   0.667   0.178               0.393   0.877   0.986   0.999
    Small sample size        1.98 (1.01--3.88)   0.048   0.941   0.133               0.315   0.835   0.981   0.998
                                                                                                             
  CC compared with TT + TC                                                                                   
    Small sample size        2.03 (1.32--3.10)   0.001   0.899   0.003               0.010   0.099   0.526   0.918
                                                                                                             
  C compared with T                                                                                          
    Small sample size        1.38 (1.12--1.68)   0.002   0.864   0.007               0.020   0.186   0.698   0.959

^a^Chi-square test was adopted to calculate the genotype frequency distributions. ^b^Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.PB, source of controls is population-based

Discussion {#sec4}
==========

Concerning the history of the *let-7* family polymorphism studies, the first report began from the year of 2011. Fang Huang et al. first screened the functional SNPs from the gene region of *let-7* gene family as well as 10 kb upstream, and they selected the *let-7i* promoter rs10877887 SNP and the *let-7a-1/let-7f-1/let-7d* gene cluster promoter rs13293512 SNP as the studied polymorphism sites \[[@B28]\]. Almost at the same time, a few other investigators adopted a similar screening strategy and selected four SNPs as the aiming-studied SNPs (*let-7a-1* rs10739971; *let-7a-2* rs629367 and rs1143770; *let-7f-2* rs17276588) \[[@B29],[@B30]\]. Although *let-7* gene family had ten gene members, only six SNPs mentioned above could be selected to study in their gene region. In our meta-analysis, only the *let-7i* rs10877887 and *let-7a-1/let-7f-1/let-7d* rs13293512 SNPs in the risk study and *let-7i* rs10877887, *let-7a-1* rs10739971, and *let-7a-2* rs629367 SNPs in the prognosis study were recruited into the pooled analysis.

The *let-7i* rs10877887 SNP was the hottest SNP in *let-7* family which all the scholars focussed on. It was located in the -286 bp region of *let-7i* gene which was the promoter region. Meanwhile, it was also located in the tail gene region of an lncRNA-linc01465. In the overall cancer risk analysis, we found that it nearly reached a statistical significance for an increased risk in recessive genetic model ([Table 4](#T4){ref-type="table"}). When stratified by cancer type, source of controls, and sample size, it was found that *let-7i* rs10877887 SNP variant genotype was associated with a decreased risk in dominate model in the subgroup of head and neck cancer, PB source of controls, and large sample size. While in the subgroup of small sample size, in all the genetic models, this rs10877887 SNP was associated with an increased cancer risk, except the co-dominate model (TC compared with TT). Then, we could analyze that the relative nonsignificance in the overall analysis was maybe due to the opposite results for the small and large sample size subgroups. We speculated this SNP seemed to tend to protect the cancer risk. Thus, more studies amplified sample size and multicenter studies are required in the future study to verify our findings.

The rs13293512 SNP located in -8496 bp upstream of the *let-7a-1/let-7f-1/let-7d* gene cluster which could be a promoter region for this gene cluster. For the *let-7a-1/let-7f-1/let-7d* rs13293512 SNP, only Longbiao Zhu et al. found that it was associated with head and neck cancer in the recessive genetic model \[[@B31]\], other three studies found no significance between this rs13293512 SNP and cancer risks. In the overall analysis, the integrated meta-analysis results also did not find this SNP had associated with cancer risk. More studies were needed to confirm this result in the future.

There is a phenomenon that even in the same kind of cancer patients with the same stage and pathological classification, the prognosis might not be the same owing to the genetic causes leading to some contributions \[[@B32]\]. It was accepted that the genetic polymorphisms could predict the cancer prognosis \[[@B33]\], and we found in this meta-analysis the *let-7i* rs10877887 SNP was associated with a higher risk for cancer prognosis in the dominate model. Due to the limited studies of the *let-7* family polymorphisms and cancer prognosis, this result need more samples to verify. And the original studies used in the meta-analysis were all hepatocellular cancer, thus this *let-7i* rs10877887 SNP maybe had the potential to be a biomarker for the specific prediction of the hepatocellular cancer prognosis.

Advantages and limitations {#sec5}
==========================

To our knowledge, this is the first time to report the association between *let-7* family polymorphisms and cancer risk/prognosis. Of course, this meta-analysis still had several limitations. First, only studies written in English and Chinese were searched in our analysis, while reports in other languages or some other ongoing studies were not available. Second, the pooled sample size was relatively limited thus we could only preliminarily appraise the association of *let-7* polymorphism with currently reported types of cancers. More studies are still required to pool together to make the analysis more reliable.

Summary and future directions {#sec6}
=============================

In summary, this meta-analysis suggested that the *let-7i* rs10877887 variant genotype was significantly associated with a decreased cancer risk in head and neck cancer, and the *let-7i* rs10877887 SNP was shown to be associated with a higher risk for cancer prognosis in the dominate model. Additional well-designed studies in larger samples and functional studies regarding *let-7* family SNPs are required to confirm our findings.
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CI

:   confidence interval

HB

:   hospital based

HR

:   hazard ratio

HWE

:   Hardy--Weinberg equilibrium

NA

:   not available

NM

:   not mentioned

OR

:   odds ratio

PB

:   population based

PCR-RFLP

:   restriction fragment length polymorphism-polymerase chain reaction

qPCR

:   quantitative polymerase chain reaction

SNP

:   single nucleotide polymorphism

TSA

:   trial sequential analysis
